Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
35.00
-0.33 (-0.93%)
At close: Dec 5, 2025, 4:00 PM EST
35.05
+0.05 (0.14%)
After-hours: Dec 5, 2025, 5:01 PM EST
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $164.86M in the quarter ending September 30, 2025, with 162.11% growth. This brings the company's revenue in the last twelve months to $435.83M, up 114.22% year-over-year. In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth.
Revenue (ttm)
$435.83M
Revenue Growth
+114.22%
P/S Ratio
7.02
Revenue / Employee
$1,132,016
Employees
385
Market Cap
3.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TVTX News
- 2 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 9 days ago - Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA - Seeking Alpha
- 17 days ago - Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally - The Motley Fool
- 25 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 - Business Wire
- 4 weeks ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter - Benzinga
- 5 weeks ago - Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript - Seeking Alpha